Status:

UNKNOWN

The Effectiveness of Transcranial Magnetic Stimulation of Supplementary Motor Area (SMA) in Patients With Bladder Hypersensitivity and Bladder Pain

Lead Sponsor:

Joint-Stock Company North-West Center for Evidence-Based Medicine, Russian Federation

Conditions:

Bladder Hypersensitivity

Eligibility:

FEMALE

18-75 years

Phase:

NA

Brief Summary

The main hypothesis of this study is that transcranial magnetic neuromodulation can correct the symptoms of hypersensitivity and bladder pain. The investigators assume that under the influence of tran...

Detailed Description

The aim of the study is to test the hypothesis that the use of the magnetic stimulation method SMA in patients with symptoms of bladder hypersensitivity and bladder pain will help to reduce the clinic...

Eligibility Criteria

Inclusion

  • Age \> 18 years;
  • Signed informed consent;
  • The presence of OAB symptoms: urinary frequency, nocturia, urgency and urge incontinence; discomfort during filling the bladder, pain in the projection of the bladder over the womb.
  • Resistance to standard therapy for bladder hypersensitivity and bladder pain.

Exclusion

  • The patient, who have been implanted devices that control physiological functions (a pacemaker, a device for deep brain stimulation and chronic epidural brain stimulation, a cochlear implant).
  • Convulsive attacks in the anamnesis;
  • Taking medications that may trigger the risk of seizures;
  • Pregnancy or suspicion on it;
  • The presence in the patient's body of metal elements or objects made with the use of ferromagnets (joint prostheses, eye prostheses, tattoos made using metal ink, surgical clips, staples and other metal suture materials, etc.)
  • Chronic cardiovascular and cerebrovascular diseases in the stage of decompensation or recent acute conditions (myocardial infarction, brain stroke, etc.)
  • A history of injuries associated with impaired conduction along the pathways of the brain and spinal cord;
  • The presence of detrusor hyperactivity patterns according to the preliminary multichannel urodynamic study;
  • The presence of infravesical obstruction in men, determined by uroflowmetry (obstructive urination curve according to the Liverpool nomogram);
  • The postvoid residual volume (more than 100 ml);
  • The presence of urinary tract infection;
  • A history of cancer;

Key Trial Info

Start Date :

January 20 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

January 20 2022

Estimated Enrollment :

28 Patients enrolled

Trial Details

Trial ID

NCT04721210

Start Date

January 20 2021

End Date

January 20 2022

Last Update

March 19 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Joint-Stock Company "North-Western Centre of Evidence-Based Medicine"

Saint Petersburg, Russia, 196158